SLE Criteria for NEET PG: The 2019 EULAR/ACR Points System and the Antibodies That Matter

The 2019 EULAR/ACR criteria turn the diagnosis of systemic lupus erythematosus (SLE) into a points exercise. A positive ANA opens the gate, each clinical or immunologic feature earns weighted points, and a total of 10 or more (with at least one clinical criterion) classifies the patient as having SLE. If you learn the table and the rules around it, you can work out a patient's score step by step instead of relying on recall.

This post sets out the entry criterion, the full points table, the rules that stop you double-counting, and how the 2019 set differs from the older ACR 1997 and SLICC 2012 sets. It then covers the antibodies, lupus nephritis classes, drug-induced lupus and neonatal lupus.

Key Takeaways

• ANA at a titre of 1:80 or higher on HEp-2 cells (or an equivalent positive test) is the entry criterion. No ANA, no classification.

• Seven clinical and three immunologic domains are scored; only the highest-weighted item in each domain counts. You need at least one clinical criterion and a total of 10 or more points.

• Anti-dsDNA and anti-Smith carry equal weight (6 points each). Neither alone reaches 10, and the classic renal biopsy (class III or IV) is the single highest item at 10.

• Anti-Smith is the more specific antibody; anti-dsDNA is the one that tracks disease activity and nephritis.

• Classification criteria are built for research, not as a bedside rule-out test.

What Are the 2019 EULAR/ACR SLE Criteria?

They are the current classification criteria for SLE, published by the European Alliance of Associations for Rheumatology (EULAR) and the American College of Rheumatology (ACR) in Aringer et al., Arthritis & Rheumatology 2019. The set has an entry criterion and then a weighted scoring system across ten domains.

The entry criterion is a positive ANA at least once, at a titre of 1:80 or higher on HEp-2 cells, or an equivalent positive test. Patients who never have a positive ANA are not classified as SLE under this system, however suggestive their other features are.

Two scoring rules matter as much as the weights:

• Within each domain, only the highest-weighted item counts. A patient with both leukopenia (3) and thrombocytopenia (4) scores 4 for the hematologic domain, not 7.
• An item counts only if SLE is the most likely explanation, with no more likely alternative cause.

To classify, you need at least one clinical criterion plus a total of 10 or more points (Oman paediatric SLE study, 2021; Barcelona cohort, 2021). The theoretical maximum is 51 points.

SLE Criteria Points Table (Domain by Domain)

Memorise this table as seven clinical domains plus three immunologic ones. The weights below come from the original 2019 paper, and a 2020 review of the new criteria confirms the renal, antiphospholipid, complement and antibody rows.

A Memory Aid for the Weights

This is an original study aid, not part of the published criteria. Think "2-3-4-5-6, then 8 and 10". The 2s are the minor items (fever, alopecia, oral ulcers, delirium, antiphospholipid antibodies), the 6s are the strong clinical and serologic signals (acute cutaneous lupus, acute pericarditis, joint involvement, anti-Smith, anti-dsDNA), and the renal biopsy classes sit above everything at 8 and 10.

Worked Scoring Arithmetic

Try this with two arithmetic examples. First, a positive ANA, joint involvement (6) and anti-dsDNA (6) give 12 points with a clinical criterion present, so the patient is classified. Second, a positive ANA, low C3 and low C4 (4) and anti-Smith (6) also total 10, but there is no clinical criterion, so the patient is not classified yet.

That second example is a useful reminder that the 10-point total is necessary but not sufficient.

Which Antibody Matters Most: Anti-dsDNA vs Anti-Smith

Anti-dsDNA and anti-Smith each score 6 points, and they are the only two SLE-specific antibodies in the table (Curr Rheumatol Rep 2020). Only one of the two is counted per patient (same domain), so a patient positive for both still scores 6 from this domain.

In practice the two do different jobs, as described in the MSD Manual and a review of drug-induced lupus:

For the 2019 criteria, the anti-dsDNA result must come from an assay with at least 90% specificity against relevant disease controls, such as the Crithidia or Farr assay (Curr Rheumatol Rep 2020).

The newer 2026 British Society for Rheumatology SLE guideline advises supplementing ANA with anti-dsDNA, ENA and C3/C4, and calls a positive anti-dsDNA, low complement or anti-Smith "highly supportive of SLE diagnosis" when relevant symptoms are present.

How the 2019 Criteria Compare With ACR 1997 and SLICC 2012

The three sets differ in structure, not just in number of items. The 2019 set added a mandatory ANA gate and weights, and it has no biopsy-alone route, unlike SLICC.

Structure and thresholds are from the Oman study and the 2026 BSR guideline. The sensitivity and specificity figures are from the 2019 validation cohort of 1,270 subjects reported in the Aringer paper abstract. Other studies quote different numbers, so do not mix them.

The practical reading is that the 2019 set kept the sensitivity of SLICC while recovering the specificity of ACR 1997.

Limits of Classification Criteria

Classification criteria are designed for research cohorts, with high specificity and lower sensitivity, and they can miss recent-onset or atypical disease. In the Barcelona longstanding-SLE study, 9 of 79 patients (11.4%) with a clinical diagnosis of SLE met none of the three sets. Agreement between sets was also modest in that cohort (kappa 0.61 for 2019 versus SLICC, 0.27 for 2019 versus ACR 1997).

Lupus Nephritis: ISN/RPS Classes and the Points Link

Lupus nephritis is graded on renal biopsy using the ISN/RPS classification, and in the 2019 table class II or V scores 8 while class III or IV scores 10. With a positive ANA, a class III or IV biopsy reaches 10 points by itself. The classes below follow Kiremitci and Ensari, 2014.

The 2018 revision of the classification dropped the IV-S and IV-G labels and replaced active and chronic labels with activity and chronicity indices (Bajema et al., Kidney Int 2018).

When to Biopsy

The MSD Manual lists protein excretion above 500 mg/day with hematuria thought to be glomerular, or red cell casts, as triggers for evaluating lupus nephritis. A Kidney Medicine review notes that KDIGO 2021 suggests biopsy for persistent urine protein-creatinine ratio above 500 mg/g.

Biopsy confirms the diagnosis, assigns the class, scores activity and chronicity, and picks up non-immune lesions. The same review puts the rate of major biopsy complications at about 2 to 3%. The 2026 BSR guideline recommends a timely kidney biopsy as part of the initial diagnosis (grade 2B).

Class can change over time, so a repeat biopsy may be warranted.

For background on glomerular syndromes, see the nephrotic versus nephritic syndrome post.

Drug-Induced Lupus vs Idiopathic SLE

Drug-induced lupus (DIL) mimics SLE but is usually milder and resolves within weeks of stopping the drug. The comparison below is from a narrative review of drug-induced lupus, supported by the MSD Manual.

Drugs implicated include hydralazine, procainamide, isoniazid, methyldopa, quinidine, minocycline and chlorpromazine, and TNF inhibitors can also cause a lupus-like syndrome. Procainamide carries the highest risk in the review (15 to 20%), followed by hydralazine (5 to 8%) and quinidine (below 1%).

Anti-histone antibodies are a marker for classic DIL but are not specific, since about half of idiopathic SLE patients also have them. This is why a negative anti-dsDNA with positive anti-histone in a patient on hydralazine points to DIL.

Neonatal Lupus and Anti-Ro/SSA

Neonatal lupus is caused by maternal IgG anti-Ro/SSA, with or without anti-La/SSB, crossing the placenta (Indian Pediatrics review, 2013). The mother may have SLE, but she may also be asymptomatic.

Cutaneous disease affects 15 to 25% of affected children and looks like subacute cutaneous lupus or annular erythema rather than a malar rash. Hepatic and hematologic involvement is usually mild, and non-cardiac features resolve within months.

Congenital heart block is the serious, irreversible complication. The figures to learn are:

• Risk with an anti-Ro-positive mother: about 1 to 2%.
• Risk when anti-La is also present: about 5%.
• Usual time of detection: 18 to 24 weeks of gestation.
• Recurrence risk in later pregnancies: 5 to 17%.

The MSD Manual recommends weekly fetal ultrasound at weeks 18 to 26 in SSA-positive pregnancies, and the BSR guideline recommends anti-Ro/SSA and anti-La/SSB reassessment before pregnancy as part of counselling (grade 1A).

Common Mistakes When Using SLE Criteria

Most scoring slips come from breaking one of the rules in the opening section. Keep these in mind when you work through a stem:

• Adding two items from the same domain instead of taking the highest.
• Forgetting the ANA entry criterion, or treating a positive ANA as diagnostic by itself.
• Reaching 10 points from immunologic items alone, with no clinical criterion.
• Counting a feature that has a more likely explanation, such as leukopenia from a drug.
• Treating a classification set as a bedside diagnostic test.

Practice the arithmetic with rheumatology practice questions, and revisit the cytopenia and hemolysis items in the anemia classification post.

Conclusion

The 2019 EULAR/ACR criteria reduce SLE to three steps: confirm the ANA, add the highest item from each domain, and check that at least one clinical criterion is present with a total of 10 or more. Anti-dsDNA and anti-Smith score the same 6 points, but anti-Smith is the more specific marker and anti-dsDNA is the one followed for activity and nephritis. A class III or IV biopsy alone earns 10 points, and drug-induced lupus and neonatal lupus are best remembered through their antibodies.

To test yourself, redraw the points table from memory and then try the NEET PG question bank for connective tissue disease questions.